Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
19 hedge funds and large institutions have $2.1M invested in Trillium Therapeutics Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
5% less capital invested
Capital invested by funds: $2.2M → $2.1M (-$102K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$38.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.8K |
| 3 |
Two Sigma Advisers
New York
|
+$9.7K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$6.2K |
| 5 |
VF
Virtu Financial
New York
|
+$5.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$24K |
| 2 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
-$2.53K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 4 |
Two Sigma Investments
New York
|
-$777 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$507 |
TRIL Hedge Fund Activity: Q3 2019 in Review
19 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2019, worth a combined $2.1M — down 4.6% from $2.2M a quarter earlier.
Fund positioning in TRIL was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $38.7K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $24K sold.
- 19 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2.1M of Trillium Therapeutics Inc. stock for Q3 2019, down 4.6% quarter-over-quarter.
- 3 funds opened new Trillium Therapeutics Inc. positions in Q3 2019 and 3 closed out, a net change of 0 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2019 was Morgan Stanley, an estimated $38.7K added.
- The largest Trillium Therapeutics Inc. seller in Q3 2019 was Samsara BioCapital, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2019.